Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.69
-0.24-5.98%
At close: -
$3.75
0.061.49%
After Hours: 7:30 PM EDT
Comments
Loading...
4D Molecular Therapeutics Analyst Ratings and Price Targets | NASDAQ:FDMT | Benzinga
4D Molecular Therapeutics Inc has a consensus price target of $35.25 based on the ratings of 13 analysts. The high is $81 issued by Goldman Sachs on February 7, 2024. The low is $6 issued by Morgan Stanley on January 13, 2025. The 3 most-recent analyst ratings were released by B of A Securities, Chardan Capital, and RBC Capital on March 10, 2025, March 4, 2025, and March 3, 2025, respectively. With an average price target of $34.33 between B of A Securities, Chardan Capital, and RBC Capital, there's an implied 815.56% upside for 4D Molecular Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Chardan Capital
RBC Capital
HC Wainwright & Co.
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for 4D Molecular Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 966.67% | B of A Securities | Tazeen Ahmad56% | $42 → $40 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | 646.67% | Chardan Capital | Geulah Livshits45% | $30 → $28 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 833.33% | RBC Capital | Luca Issi42% | $39 → $35 | Maintains | Outperform | Get Alert |
| 03/03/2025 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 700% | Chardan Capital | Geulah Livshits45% | $39 → $30 | Maintains | Buy | Get Alert |
| 02/10/2025 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 60% | Morgan Stanley | Judah Frommer65% | $8 → $6 | Maintains | Underweight | Get Alert |
| 01/13/2025 | Buy Now | 620% | Leerink Partners | Mani Foroohar46% | $31 → $27 | Maintains | Outperform | Get Alert |
| 01/13/2025 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 1126.67% | B of A Securities | Tazeen Ahmad56% | $79 → $46 | Maintains | Buy | Get Alert |
| 11/21/2024 | Buy Now | 113.33% | Morgan Stanley | Judah Frommer65% | → $8 | Initiates | → Underweight | Get Alert |
| 11/14/2024 | Buy Now | 940% | Chardan Capital | Geulah Livshits45% | $39 → $39 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 940% | RBC Capital | Luca Issi42% | $40 → $39 | Maintains | Outperform | Get Alert |
| 09/23/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer55% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/19/2024 | Buy Now | 940% | Chardan Capital | Geulah Livshits45% | $38 → $39 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 860% | Leerink Partners | Mani Foroohar46% | $40 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 09/19/2024 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer55% | — | Reiterates | → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 966.67% | RBC Capital | Luca Issi42% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 07/18/2024 | Buy Now | 966.67% | BMO Capital | Kostas Biliouris34% | $63 → $40 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | 913.33% | Chardan Capital | Geulah Livshits45% | $38 → $38 | Maintains | Buy | Get Alert |
| 06/26/2024 | Buy Now | 966.67% | RBC Capital | Luca Issi42% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2024 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2024 | Buy Now | 966.67% | RBC Capital | Luca Issi42% | $35 → $40 | Maintains | Outperform | Get Alert |
| 04/15/2024 | Buy Now | 1100% | Barclays | Gena Wang51% | → $45 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 1580% | BMO Capital | Kostas Biliouris34% | $70 → $63 | Maintains | Outperform | Get Alert |
| 04/01/2024 | Buy Now | 1446.67% | Jefferies | Nalin Tejavibulya55% | $30 → $58 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | Buy Now | 2060% | Goldman Sachs | Salveen Richter53% | → $81 | Reinstates | → Buy | Get Alert |
| 02/05/2024 | Buy Now | 1766.67% | BMO Capital | Kostas Biliouris34% | $50 → $70 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 833.33% | RBC Capital | Luca Issi42% | $25 → $35 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | 566.67% | RBC Capital | Luca Issi42% | → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | 753.33% | Cantor Fitzgerald | Josh Schimmer55% | → $32 | Initiates | → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 726.67% | Chardan Capital | Geulah Livshits45% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 726.67% | Chardan Capital | Geulah Livshits45% | $30 → $31 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 700% | Chardan Capital | Geulah Livshits45% | → $30 | Initiates | → Buy | Get Alert |
| 06/08/2023 | Buy Now | 780% | B of A Securities | Tazeen Ahmad56% | $28 → $33 | Maintains | Buy | Get Alert |
| 06/08/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 246.67% | SVB Securities | Mani Foroohar46% | $14 → $13 | Maintains | Market Perform | Get Alert |
| 03/16/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 273.33% | SVB Leerink | Mani Foroohar46% | $15 → $14 | Maintains | Market Perform | Get Alert |
| 01/30/2023 | Buy Now | 1233.33% | BMO Capital | Kostas Biliouris34% | → $50 | Initiates | → Outperform | Get Alert |
| 11/18/2022 | Buy Now | 860% | HC Wainwright & Co. | Matthew Caufield40% | → $36 | Initiates | → Buy | Get Alert |
| 11/15/2022 | Buy Now | 1713.33% | Goldman Sachs | Salveen Richter53% | → $68 | Upgrade | Neutral → Buy | Get Alert |
| 11/14/2022 | Buy Now | 300% | SVB Leerink | Mani Foroohar46% | $11 → $15 | Maintains | Market Perform | Get Alert |
| 11/10/2022 | Buy Now | 193.33% | SVB Leerink | Mani Foroohar46% | $10 → $11 | Maintains | Market Perform | Get Alert |
| 08/12/2022 | Buy Now | 220% | SVB Leerink | Mani Foroohar46% | $28 → $12 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/22/2022 | Buy Now | 486.67% | Jefferies | Nalin Tejavibulya55% | → $22 | Initiates | → Buy | Get Alert |
| 05/13/2022 | Buy Now | 646.67% | SVB Leerink | Mani Foroohar46% | $30 → $28 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for 4D Molecular Therapeutics (FDMT) stock?
The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by B of A Securities on March 10, 2025. The analyst firm set a price target for $40.00 expecting FDMT to rise to within 12 months (a possible 966.67% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 4D Molecular Therapeutics (FDMT)?
The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by B of A Securities, and 4D Molecular Therapeutics maintained their buy rating.
When was the last upgrade for 4D Molecular Therapeutics (FDMT)?
The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.
When was the last downgrade for 4D Molecular Therapeutics (FDMT)?
The last downgrade for 4D Molecular Therapeutics Inc happened on September 23, 2024 when Cantor Fitzgerald changed their price target from N/A to N/A for 4D Molecular Therapeutics Inc.
When is the next analyst rating going to be posted or updated for 4D Molecular Therapeutics (FDMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating 4D Molecular Therapeutics (FDMT) correct?
While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a maintained with a price target of $42.00 to $40.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $3.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.